S&P 5005,963+0.54%
NASDAQ21,443+0.87%
DOW43,892+0.31%
DAX23,888+0.44%
FTSE 1008,721-0.12%
EUR/USD1.1465+0.07%
GBP/USD1.3220+0.14%
USD/JPY161.31-0.03%
Gold3,241+0.22%
WTI Oil76.40+0.81%
Bitcoin103,241+1.43%
10Y UST4.47%-9bp
S&P 5005,963+0.54%
NASDAQ21,443+0.87%
DOW43,892+0.31%
DAX23,888+0.44%
FTSE 1008,721-0.12%
EUR/USD1.1465+0.07%
GBP/USD1.3220+0.14%
USD/JPY161.31-0.03%
Gold3,241+0.22%
WTI Oil76.40+0.81%
Bitcoin103,241+1.43%
10Y UST4.47%-9bp
MarketsFN
Home/Hedge Funds/Adar1 Capital Management/Q4 2024

Adar1 Capital Management

Period: Q4 2024 Β· Filed: 2025-02-13
View on SEC EDGAR β†—
AUM
$500M
Total portfolio value
Positions
214
Reported securities
Top Holding
ROIV
8.3% $41.5M
QoQ Changes
+8 / -8
new Β· exited
⚠️13F Filing Disclosure

AUM figures shown are calculated by summing the reported market value of all positions in SEC 13F-HR filings β€” not the fund's actual assets under management.

  • Excludes cash, bonds, private equity, short positions, and foreign-listed stocks not required to be reported.
  • For PUT and CALL options, the reported Value is the notional value of the underlying shares β€” not the option premium paid. This significantly overstates the actual capital at risk.
  • Actual fund AUM is typically higher and includes strategies, instruments, and positions that never appear in a 13F.
  • 13F filings cover institutional managers with β‰₯$100M in 13F securities. Positions reflect end-of-quarter holdings, disclosed up to 45 days after the period ends.

Data sourced from SEC EDGAR. This tracker is for informational purposes only and does not constitute investment advice.

Portfolio Holdings

Top 30 positions

⚠️ Performance % calculated from filing date ( 2025-02-13) shown is the underlying stock price movement β€” not the derivative's P&L.
TickerIssuerNotionalPort %@ FilingNow (EOD)Since FilingAllocation
ROIVROIVANT SCIENCES LTD$41.5M8.30%$11.83$35.13+197.0%
8.3%
PTGXPROTAGONIST THERAPEUTICS INC$39.4M7.87%$38.60$131.62+241.0%
7.9%
BOXXEA SERIES TRUST$35.9M7.17%$110.28$117.22+6.3%
7.2%
ZLABZAI LAB LTD$27.4M5.47%$26.19$19.12-27.0%
5.5%
IMVTIMMUNOVANT INC$19.5M3.90%$24.77$38.79+56.6%
3.9%
CYTKCYTOKINETICS INC$19.5M3.89%$47.04$86.49+83.9%
3.9%
BBIOBRIDGEBIO PHARMA INC$18.6M3.72%$27.44$77.19+181.3%
3.7%
IKTINHIBIKASE THERAPEUTICS INC$16.6M3.31%$3.25$1.99-38.8%
3.3%
BILSPDR SER TR$12.1M2.41%$86.49$91.44+5.7%
2.4%
ABVXABIVAX SA$11.1M2.21%$7.32$144.65+1876.1%
2.2%
MLYSMINERALYS THERAPEUTICS INC$10.4M2.07%$12.31$27.69+124.9%
2.1%
ASNDASCENDIS PHARMA A/S$9.8M1.96%$137.67$274.50+99.4%
2.0%
PCSCPERCEPTIVE CAP SOLUTIONS COR$7.6M1.53%$10.18$11.00+8.1%
1.5%
RVMDREVOLUTION MEDICINES INC$7.4M1.49%$43.74$189.24+332.6%
1.5%
RZLTREZOLUTE INC$6.7M1.33%$4.90$4.91+0.2%
1.3%
EDRENDEAVOR GROUP HLDGS INC$6.6M1.32%β€”β€”
1.3%
CGONCG ONCOLOGY INC$6.2M1.24%$28.68$70.36+145.3%
1.2%
AVRANTERIS TECHNOLOGIES GLOBAL$5.9M1.17%$5.58$10.24+83.5%
1.2%
AAMAA MISSION ACQUISITION CORP$5.7M1.13%β€”β€”
1.1%
COHERUS BIOSCIENCES INC$5.5M1.09%β€”β€”
1.1%
XNCRXENCOR INC$5.4M1.08%$22.98$15.00-34.7%
1.1%
ZURAZURA BIO LTD$5.2M1.04%$2.50$5.17+106.8%
1.0%
PTGXCALLPROTAGONIST THERAPEUTICS INC$5.1M1.02%$38.60$131.62+241.0%
1.0%
ABUSARBUTUS BIOPHARMA CORP$5.1M1.02%$3.27$4.87+48.9%
1.0%
OACCUOAKTREE ACQUISITION CORP III$5.1M1.01%$10.13$11.00+8.6%
1.0%
SRPTSAREPTA THERAPEUTICS INC$4.9M0.97%$121.59$19.28-84.1%
1.0%
SNYSANOFI$4.8M0.96%$43.76$43.16-1.4%
1.0%
XBICALLSPDR SER TR$4.5M0.90%$89.64$160.46+79.0%
0.9%
GOSSAMER BIO INC$4.4M0.87%β€”β€”
0.9%
HLXBHELIX ACQUISITION CORP II$4.2M0.85%β€”β€”
0.8%

Quarter-on-Quarter Activity

Q4 2024 vs. Q3 2024

New Positions (8)

TickerIssuerNotionalSince Filing
IKTINHIBIKASE THERAPEUTICS INC$16.6M-38.8%
AVRANTERIS TECHNOLOGIES GLOBAL$5.9M+83.5%
COHERUS BIOSCIENCES INC$5.5M
OACCUOAKTREE ACQUISITION CORP III$5.1M+8.6%
SNYSANOFI$4.8M-1.4%
GOSSAMER BIO INC$4.4M
BRIDGEBIO PHARMA INC$3.9M
MNPRMONOPAR THERAPEUTICS INC$2.9M

Exited Positions (8)

TickerIssuerNotional
SNDXSYNDAX PHARMACEUTICALS INC$6.7M
QTTBQ32 BIO INC$2.9M
PIRSPIERIS PHARMACEUTICALS INC$2.4M
NVONOVO-NORDISK A S$2.4M
SNDXSYNDAX PHARMACEUTICALS INC$2.0M
MCKMCKESSON CORP$1.5M
BNTXBIONTECH SE$1.2M
NVONOVO-NORDISK A S$1.2M

Increased (8)

TickerIssuerNotionalShares Ξ”Since Filing
PHATCALLPHATHOM PHARMACEUTICALS INC$0.5M+27600.0%
RAPTRAPT THERAPEUTICS INC$1.8M+15557.5%
ACHVACHIEVE LIFE SCIENCES INC$0.1M+14375.8%
ETNB89BIO INC$4.0M+7752.7%
KROSKEROS THERAPEUTICS INC$0.3M+7648.7%
IMVTIMMUNOVANT INC$19.2M+7620.4%+56.6%
APLTCALLAPPLIED THERAPEUTICS INC$0.4M+5976.8%
PHATCALLPHATHOM PHARMACEUTICALS INC$0.1M+4950.0%

Trimmed (8)

TickerIssuerNotionalShares Ξ”Since Filing
CYTKCALLCYTOKINETICS INC$-47.4M-98.3%+83.9%
MOVEMOVANO INC$-0.3M-98.3%
RGNXCALLREGENXBIO INC$-5.8M-96.9%
AMLXCALLAMYLYX PHARMACEUTICALS INC$-0.7M-95.5%
RPRXROYALTY PHARMA PLC$-29.8M-95.4%
GOSSCALLGOSSAMER BIO INC$-0.4M-95.2%
KROSKEROS THERAPEUTICS INC$-25.5M-94.8%
BIIBBIOGEN INC$-5.3M-89.7%
← Back to Hedge Funds